A review of imaging agent development

Area of Science:

• Nuclear medicine and molecular imaging.
• Radiopharmaceutical chemistry and development.
• Translational research in diagnostics.

Background:

• The discovery and development of imaging agents, particularly positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers, are crucial for medical diagnostics.
• While sharing similarities with drug development, imaging agent creation requires specific criteria for target selection and imageability.
• Preclinical imaging serves as a vital translational tool for validating mechanisms and concepts before clinical application.

Purpose of the Study:

• To provide an educational review of the processes, opportunities, and challenges in discovering and developing novel imaging agents.
• To highlight the unique considerations for imaging agent development compared to traditional pharmaceuticals.
• To discuss strategies for overcoming bottlenecks and accelerating the clinical translation of imaging tracers.

Main Methods:

• Review of existing literature and industry practices in imaging agent development.
• Analysis of the parallel processes and unique requirements in drug versus imaging agent discovery.
• Discussion of market, intellectual property, radiolabeling, and target concentration challenges.

Main Results:

• Imaging agent development allows targeting of functional or non-functional disease-related targets if they meet imageability criteria.
• Key challenges include small market sizes, intellectual property hurdles, radiolabeling limitations, and achieving adequate target concentrations.
• Collaborative approaches, such as microdosing and theranostics, show promise in accelerating clinical translation.

Conclusions:

• Successful imaging agent development requires navigating specific scientific, regulatory, and market challenges.
• Strategic partnerships between pharmaceutical and imaging companies are essential for efficient clinical translation.
• Continued innovation in imaging agents, supported by preclinical research and collaborative models, is vital for advancing medical diagnostics.